Why use a Premade Library for Autoimmune Disease targets instead of animal immunization?

The most critical challenge in autoimmune research is immune tolerance. Since many disease targets are "self-antigens," traditional animal immunization often fails to produce high-affinity antibodies because the animal's immune system suppresses binders to its own proteins. Our Premade Human Antibody Libraries circumvent this by using in vitro selection, allowing us to identify potent binders against highly conserved human self-antigens that are otherwise "invisible" to in vivo methods.

Can you discover antibodies that distinguish between different conformational states of a cytokine?

Yes. Many autoimmune pathologies involve specific active conformations of cytokines or signaling molecules. By using Phage or Yeast Display, we can perform differential panning. We use the inactive or monomeric form as a negative decoy and the active or multimeric form as the positive target, ensuring the resulting antibodies specifically modulate the disease-associated state without interfering with basal physiological functions.

How do you address the need for "Effector-Silent" antibodies in autoimmune therapy?

In many autoimmune applications (e.g., blocking a receptor without killing the cell), the antibody's Fc-mediated effector functions (ADCC, CDC) must be minimized to avoid unintended tissue damage. While our libraries provide the binding variable regions (VH/VL), we offer specialized isotype switching to IgG4 or engineered IgG1 to ensure the final candidate is effector-silent and safe for chronic administration.

What information do I need to provide to start my autoimmune project?

To tailor our screening strategy, we recommend providing: Target Details: Protein sequence, specific domains of interest, or cell lines expressing the target. Mechanism of Action (MoA): Whether you need an antagonist (blocker), agonist, or a depleting antibody. Benchmarking: If there is a gold standard clinical antibody, we can include it as a positive control in our validation assays.

Autoimmune Disorder Specific Antibody Discovery Service by Premade Library

Screening Services Workflow Premade Libraries Cases Related Services Why Choose Us? FAQ

Developing therapies for autoimmune disorders requires navigating a minefield: targets are often "self" proteins, requiring antibodies that can break tolerance, achieve high affinity to compete with endogenous ligands, and remain non-immunogenic for chronic dosing. Creative Biolabs combines massive premade antibody libraries (up to 10¹¹ diversity) with specialized screening strategies engineered to identify rare, functional modulators of the immune system.

Your Perfect Solution Awaits. Request a Quote.

From Vast Diversity to Functional Autoimmune Therapeutics, Faster Than Ever.

Autoimmune drug discovery faces a unique paradox where you must target the host's own proteins with high potency while avoiding off-target toxicity. Conventional immunization often fails due to natural immune tolerance mechanisms. Creative Biolabs' Premade Antibody Library Service bypasses the host immune system entirely. By leveraging our massive synthetic and naïve antibody libraries paired with high-stringency functional screening, we identify high-affinity antagonists and signaling modulators that conventional methods cannot reach. This strategic approach delivers developable, clinic-ready candidates in weeks rather than months.

At Creative Biolabs, our phage and yeast display platforms are tuned to traverse the vastness of our premier libraries with surgical precision. We employ tolerance-breaking panning strategies, such as alternating antigen formats and stringent washing, to isolate rare clones that bind effectively to self-antigens. We integrate functional assays early in the process. We screen not just for binding but for the specific ability to block cytokine receptors or engage inhibitory checkpoints, ensuring we deliver potent therapeutic leads instead of simple binders.

Break Tolerance

Proven strategies to isolate binders against highly conserved "self" antigens.

Functional Modulation

Direct selection for antagonism (blocking) or agonism (inhibitory pathways).

Low Immunogenicity

Fully human frameworks optimized for safety in chronic autoimmune indications.

Cross-Species Reactivity

Strategy-driven selection for surrogate evaluation in animal models.

Have Questions? Get a Quote Tailored to Your Needs

Workflow

Discovery Strategy & Antigen Design

Ensures targeting of pathogenic epitopes while avoiding healthy tissue cross-reactivity.
Tolerance-Breaking Biopanning

Overcomes natural immune silence to find rare binders against self-antigens.
Single-Clone Specificity Triage

Eliminates sticky binders early.
Functional Selection

Identifies candidates that actively modulate the disease pathway, not just bind the target.
Sequence Analytics

NGS-driven clonotype clustering.
Expression & IgG Conversion

Mini-panel IgG expression and validation

Get Started Now. Request Your Free Quote.

Ready-to-Screen Antibody Libraries

Jump to the ideal starting point for your autoimmune program:

Human Camel Llama Alpaca Humanized V_HH

Antibody Library ID	Display Technology	Library Format	Library Size
HuScL-6 ☆Highly Recommended	pIII-fusion, Phagemid Phage Display	Naïve scFv	2.1×10¹¹
HuScL-3S	pIII-fusion, Phagemid Phage Display	Semi-synthetic scFv	>1.0×10¹¹
HuFabL-4	pIII-fusion, Phagemid Phage Display	Naïve Fab	1.9×10¹⁰
HuFabssL-1	pIII-fusion, Phagemid Phage Display	Naïve & synthetic Fab	1.8×10¹⁰

Not sure which library fits? Request a Quote

Case Study: High-Diversity Libraries, High-Impact Outcomes

High-Precision Antibody Discovery for Highly Homologous Autoimmune Targets

Background

In the treatment of autoimmune disorders such as Systemic Lupus Erythematosus (SLE), targeting specific immune cell receptors is vital. However, many of these receptors belong to families with extreme structural similarity. A prime example is a specific Fc-gamma Receptor Isoform (Target B), which must be targeted without cross-reacting with its closely related Isoform A. Mis-targeting can lead to severe off-target effects, such as the unintended activation or depletion of incorrect leukocyte populations.

Challenge

The "Needle in a Haystack" Epitope Discovery
The Target Protein (Isoform B) and its Control Homolog (Isoform A) share >96% amino acid sequence identity. The differentiating epitopes are limited to only a few residues. Standard screening typically yields backbone binders that recognize the conserved regions shared by both proteins. To succeed, the screening process must be sensitive enough to detect rare clones with exclusive specificity for the remaining 4% of divergent residues.

Our Solution

We leveraged our proprietary Premade Human scFv Library and implemented a rigorous multi-stage subtractive strategy:

Pre-discovery Support
We provided a deep-dive sequence analysis to map the divergent residues and advised on the optimal expression system for the antigens to ensure native-state folding, which is crucial for distinguishing subtle surface-exposed differences.
Negative Selection (Depletion)
In every round, the library was heavily depleted against the Control Homolog (Isoform A) to exhaust clones binding to the common backbone.
Positive Selection
Enrichment was targeted against the Biotinylated Target Protein (Isoform B).

Key Results & Validation Data

1. Successful Library Enrichment
The selection process demonstrated exponential enrichment. By the fifth round, the output-to-input ratio showed a clear convergence toward target-specific binders, overcoming the high background of the control homolog.
Fig.7 Graph illustrating the library screening outcomes. (Creative Biolabs Original)

Fig.7 Graph illustrating the library screening outcomes. (Creative Biolabs Original)

Figure 7. Enrichment Kinetics Against High-Homology Targets. The recovery profile across 5 rounds of panning illustrates the effectiveness of the subtractive strategy in enriching rare binders despite the presence of 96% sequence identity with the control.
2. Multi-Stage Monoclonal Identification
Hundreds of clones were screened via high-throughput Monoclonal Phage ELISA followed by Soluble ELISA validation to ensure the specificity was maintained in both formats.

Fig.8 Graph displaying the phage ELISA validation results. (Creative Biolabs Original)

Initial screening identifying clones with a high signal-to-noise ratio between Target B and Control A.

Fig.9 Graph displaying the soluble ELISA validation results. (Creative Biolabs Original)

Final validation of 3 unique lead clones. The candidates exhibit strong positive signals for the Target Protein with baseline signals against the Control Homolog, confirming the successful isolation of isoform-specific binders.

3. SPR Characterization To confirm that the specificity was driven by high-quality binding kinetics rather than concentration artifacts, the candidates were analyzed via Surface Plasmon Resonance (SPR) across three different formats (scFv, Fusion, and full IgG).

SPR confirmed the affinity differential. The lead antibody bound to the Target Protein with nanomolar affinity (10^-7 M range), while binding to the Control Homolog was 10-fold weaker (10^-6 M).
The specificity profile remained consistent regardless of the antibody format, proving the epitope recognition is intrinsic to the CDRs and providing a robust therapeutic window for further development.

Post-Discovery Technical Support

Format Engineering: We assisted the client in evaluating which format (scFv vs. IgG) best suited their specific autoimmune MOA (e.g., blocking immune complex binding vs. receptor modulation).
Developability Profiling: We provided CDR stability analysis to ensure the leads were suitable for long-term clinical formulation.

Find Your Options. Request a Quote.

Related Services

Fig.10 Anti-Disease-specific Target Antibody Discovery. (Creative Biolabs Authorized)

Anti-tumor-specific Target Antibody Discovery

Anti-infectious disease-specific Antibody Discovery

Anti-inflammation disease-specific Antibody Discovery

Anti-allograft rejection-specific Antibody Discovery

Why Choose Us?

Breaking Tolerance Strategy

Our panning protocols are engineered to overcome immune tolerance, successfully isolating binders against conserved "self" antigens that immunization fails to find.

Functional-First Decisions

We don't just find binders; we integrate cell-based antagonism/agonism assays early to ensure leads modulate the disease pathway effectively.

Low Immunogenicity by Design

Our libraries utilize validated antibody frameworks, reducing the risk of ADA responses in chronic therapy settings.

Library-Screening Synergy

Combining 10¹¹ diversity with expert functional triage yields high-specificity binders that distinguish pathogenic targets from healthy tissue.

Weeks, Not Months

Our streamlined enrichment-to-IgG conversion pipeline bypasses the months-long immunization process, accelerating speed-to-lead.

Radical Transparency

You receive full sequence data and project report, enabling confident decisions for your studies.

Customize Your Package. Get Pricing

Ready to move fast? Creative Biolabs will scope your target, advise on best library and protocol, and get screening up and running as soon as possible.

FAQ

Why use a Premade Library for Autoimmune Disease targets instead of animal immunization?
The most critical challenge in autoimmune research is immune tolerance. Since many disease targets are "self-antigens," traditional animal immunization often fails to produce high-affinity antibodies because the animal's immune system suppresses binders to its own proteins. Our Premade Human Antibody Libraries circumvent this by using in vitro selection, allowing us to identify potent binders against highly conserved human self-antigens that are otherwise "invisible" to in vivo methods.
Can you discover antibodies that distinguish between different conformational states of a cytokine?
Yes. Many autoimmune pathologies involve specific active conformations of cytokines or signaling molecules. By using Phage or Yeast Display, we can perform differential panning. We use the inactive or monomeric form as a negative decoy and the active or multimeric form as the positive target, ensuring the resulting antibodies specifically modulate the disease-associated state without interfering with basal physiological functions.
How do you address the need for "Effector-Silent" antibodies in autoimmune therapy?
In many autoimmune applications (e.g., blocking a receptor without killing the cell), the antibody's Fc-mediated effector functions (ADCC, CDC) must be minimized to avoid unintended tissue damage. While our libraries provide the binding variable regions (VH/VL), we offer specialized isotype switching to IgG4 or engineered IgG1 to ensure the final candidate is effector-silent and safe for chronic administration.
What information do I need to provide to start my autoimmune project?
To tailor our screening strategy, we recommend providing: Target Details: Protein sequence, specific domains of interest, or cell lines expressing the target. Mechanism of Action (MoA): Whether you need an antagonist (blocker), agonist, or a depleting antibody. Benchmarking: If there is a gold standard clinical antibody, we can include it as a positive control in our validation assays.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: